Skip to main content
. 2021 Dec 17;15(2):228–239. doi: 10.1159/000521164

Table 2.

Baseline and follow-up measurements in evaluable participants (IN: n = 93; CON: n = 54)

Parameters Grp Baseline 10 weeks 6 months 1 year Changes (baseline to 1 year) p WG§ p BG#
Body weight, kg IN 81.3±1.9 77.9±1.7 76.9±1.6 77.4±1.7 −3.9 (−4.9, −2.9) <0.001a <0.001c <0.001d
CON 83.1±2.7 82.9±2.6 82.4±2.5 82.7±2.5 −0.4 (−1.6, 0.8) 0.473b

BMI, kg/m2 IN 27.6±0.5 26.4±0.5 26.1±0.5 26.3±0.5 −1.3 (−1.6, −1.0) <0.001a <0.001c <0.001d
CON 28.1±0.8 28.0±0.8 27.9±0.8 27.9±0.8 −0.1 (−0.5, 0.3) 0.662a

WC, cm IN 99±2 95±1 93±1 92±1 −6 (−7, −5) <0.001a <0.001c <0.001d
CON 97±2 97±2 96±2 96±2 −1 (−3, 1) 0.270b

TC, mg/dL IN 207±4 184±4 198±4 207±4 −1 (−6, 5) 0.806b 0.035c 0.019d
CON 208±6 207±6 198±6 207±7 −1 (−8, 5) 0.725b

Meas. LDL-C, mg/dL IN 133±4 118±3 129±4 136±4 3 (−2, 8) 0.211b 0.142c 0.113d
CON 140±6 136±6 138±6 138±6 −2 (−8, 4) 0.534b

Calc. LDL-C, mg/dL IN 121±4 103±3 110±4 120±4 −1 (−6, 4) 0.753b 0.008c 0.005d
CON 124±6 121±6 115±5 126±6 2 (−3, 8) 0.534a

Non-HDL-C, mg/dL IN 141±4 123±4 131±4 141±5 0 (−5, 5) 0.987b 0.005c 0.003d
CON 145±6 144±6 138±6 148±6 3 (−3, 10) 0.294a

REM-C, mg/dL IN 8±1 5±1 2±1 5±1 −3 (−5, −2) <0.001a 0.003c 0.002d
CON 6±2 8±2 0±2 11±1 5 (2, 8) <0.001a

HDL-C, mg/dL IN 66±2 61±2 67±2 65±2 −1 (−3, 1) 0.418a 0.160c 0.208d
CON 63±2 62±3 60±2 59±2 −5 (−7, −2) <0.001a

TAG, mg/dL IN 103±5 102±5 105±5 107±5 4 (−3, 11) 0.168a 0.346c 0.245d
CON 113±11 116±9 120±10 112±9 −1 (−18, 16) 0.485a

Glucose, mg/dL IN 99±1 94±1 96±1 99±1 0 (−2, 2) 0.990b 0.007c 0.004d
CON 101±2 99±2 103±3 102±3 1 (−3, 5) 0.966a

HbA1c, % IN 5.4±0.0 5.4±0.0 5.4±0.0 5.4±0.0 0.0 (−0.1, 0.1) 0.790a 0.002c <0.001d
CON 5.4±0.1 5.5±0.1 5.6±0.1 5.6±0.1 0.2 (0.1, 0.2) <0.001a

Insulin, µU/mL IN 12±2 13±3 −1 (−4, 1) 0.790a 0.143c 0.126d
CON 12±1 12±1 12±1 12±1 0 (−2, 1) <0.001a

Systolic BP, mm Hg IN 134±2 127±2 129±2 126±2 −8 (−11, −5) <0.001b 0.518c 0.440d
CON 132±2 127±2 127±2 127±2 −5 (−8, −2) 0.005a

Diastolic BP, mm Hg IN 81±1 78±1 79±1 77±1 −4 (−6, −2) <0.001a 0.744c 0.639d
CON 80±1 78±1 77±1 77±1 −3 (−5, −1) 0.001 b

PP, mm Hg IN 53±1 50±1 50±1 49±1 −4 (−6, −2) 0.001 a 0.609c 0.100d
CON 52±2 49±2 50±2 51±2 −2 (−5, 1) 0.133a

RHR, beats/min IN 68±1 63±1 66±1 64±1 −4 (−6, −2) <0.001a 0.006c 0.009d
CON 70±1 69±2 69±2 69±2 −1 (−4, 1) 0.208b

Values are means ± SEM, except for qualitative variables which are expressed as n (%). Changes are expressed as means and 95% CI; WC: n = 53 (CON); TC, measured LDL-C, non-HDL-C, REM-C, HDL-C, TAG, glucose, and insulin: n = 92 (IN), n = 53 (CON); calculated LDL-C: n = 92 (IN), n = 52 (CON); HbA1c: n = 91 (IN), n = 53 (CON); systolic/diastolic BP, PP, and RHR: n = 52 (CON). SEM, standard error of the mean; CI, confidence interval; p WG, p values for within-group changes from baseline to 1 year; p BG, p values for between-group differences in 1-year trajectories; IN, intervention; CON, control; Grp, group; Meas. LDL-C, measured LDL, cholesterol; Calc. LDL-C, calculated LDL-C.

§

p value for within-group comparisons by the a Wilcoxon test (two-sided) and b paired t test (two-sided).

#

p value for between-group comparisons by c repeated measures ANCOVA, adjusted for the baseline and d repeated measures ANCOVA, adjusted for baseline, age, and sex.